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Abstract
Background
Intentional drug overdose is the most common method of self-harm. As psychiatric disor-
ders are very common in self-harm patients, the medication used to treat these disorders
can become the means for the self-harm act. The present study aimed at investigating an
association between the use of prescribed medication (analgesics and antipyretics, anti-epi-
leptics, antipsychotics, antidepressants and psychostimulants) as a method of self-harm
and prescription rates of this medication in Flanders. We investigated the possible effect of
gender, alcohol use during the self-harm act and a history of self-harm.
Methods
Data from the multicenter study of self-harm in Flanders between 2008 and 2013 were
used. The significance of differences in percentages was calculated by GEE and the
strength by odds ratios (OR).
Results
There was an increase in the odds of using antidepressants (0.8%) and antipsychotics (2%)
among females when the rate of prescription increases. Analgesics and antipyretics (39.3/
1,000) and antidepressants (124.9/1,000) were the most commonly prescribed drugs
among females. Antidepressants (63.9/1,000) and antipsychotics (26.5/1,000) were the
most commonly prescribed drugs among males. Antidepressants and analgesics and anti-
pyretics were the most frequently used medications for self-harm. Analgesics and antipyret-
ics during the self-harm act were more common among first-timers, while repeaters more
commonly overdosed using antipsychotics and antidepressants.
Conclusion
These findings suggest that the availability of medication via prescriptions plays an impor-
tant role in the choice of the medication ingested during the self-harm act. Precautions are
necessary when prescribing medication, including restrictions on the number of prescrip-
tions and the return of unused medication to pharmacies after cessation of treatment. These
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issues should be a focus of attention in the education and training of physicians and
pharmacists.
Introduction
Suicidal behaviour continues to pose major challenges to (mental) health care. Suicidal behav-
iour is closely associated with mental health problems, with the most common being depres-
sion, substance use and anxiety disorders [1–4], so their treatment can be expected to
contribute substantially to suicide prevention. However, the effect of psychotropic medication
on suicidal behaviour is a matter of debate since decades. The possibility that the use of antide-
pressants may lead to an increase in suicidal behaviour has led the Food and Drug Administra-
tion (FDA) to introduce a black-box warning, following which their use decreased but suicide
rates increased in particular age groups [5]. In addition, while psychotropic drugs have an
established efficacy in treating psychiatric disorders, early pharmaco-epidemiological studies
have suggested a positive correlation between rates of their prescription and those of their use
in non-fatal suicidal behaviour [6, 7]. A recent study showed that subjects using a psychotropic
drug during a self-harm act are more likely to have had recent prescribed access to any psycho-
tropic drug and to the drug type used prior to the self-harm episode when compared to those
not using any psychotropic drug in a self-harm episode [8]. A better understanding of the link
between rates of drug prescriptions and those of self-harm acts can be expected to contribute
substantially to the prevention of suicide. For every suicide there are many more people who
attempt suicide every year [9]. A prior self-harm act is the single most important risk factor for
suicide in the general population and intentional drug overdose is the most common method
of self-harm in people who present to hospital, being used in 68 to 80% of self-harm episodes
[10–16]. Previous studies have documented a positive association between alcohol use and
self-harm [17, 18]. Consuming alcohol within six hours of and as part of the act of self-harm
increases the lethality of acts of self-poisoning, e.g. those involving paracetamol, co-proxamol
and sedatives [19]. The majority of self-harm cases involve their own home medication or pre-
scribed medications, while over-the-counter (OTC) medications are less likely to be chosen
for self-harm acts [20–23]. Given these consistent epidemiological findings it can be hypothe-
sized that the rate of prescribing of medication influences the occurrence and characteristics of
non-fatal suicidal behaviour. In addition, the association between the use of prescribed medi-
cation during a self-harm act and prescription rates in Flanders has not yet been investigated.
This study extends previous research by utilizing two large Flemish monitoring systems.
The present study therefore aimed at investigating an association between the use of pre-
scribed medication as a method of self-harm and prescription rates of these medications in
Flanders. We hypothesized that an increase in rates of prescribing is associated with an
increase in the number of non-fatal self-harm acts with that medication. We thereby investi-
gated the possible effects of gender and also the effects of alcohol use during the self-harm act
and a history of self-harm as they are strongly associated with suicidal behaviour [17, 24, 25].
Method
Definitions
The general term suicidal behaviour refers to a range of thoughts and behaviours i.e. suicide
ideation, deliberate self-harm, attempted suicide and suicide [26]. The term ‘attempted suicide’
is commonly used for episodes in which there was at least some suicidal intent (i.e. a wish to
die). The term ‘deliberate self-harm’ is often used regardless of intent which implies that
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ascribing intent is avoided rather than implying a lack of intent [27]. In this paper we used the
term ‘self-harm’, as this term refers to self-injury or intentional self-poisoning regardless of
apparent motivation or the extent of suicidal intent [28, 29]. We prefer to use the term ‘self-
harm’ instead of ‘deliberate self-harm’ because the prefix ‘deliberate’ is judgmental while the
extent to which the behaviour is intentional is not always clear [28]. The monitoring study
uses the following definition of self-harm: “an act with nonfatal outcome, in which an individ-
ual initiates a deliberate, well-considered, and unusual behaviour, that without intervention of
another will lead to self-harm or destruction, or when an individual deliberately takes a sub-
stance in higher quantity then subscribed or generally suitable doses, with the intention by
means of actual expected physical consequences to initiate desired changes” [30]. This defini-
tion was developed by the WHO/Euro Multicentre Study.
Catchment area and population under study
Flanders is a district in the northern part of Belgium, bordering with The Netherlands, Ger-
many and France. In 2013 there were 6,381,859 inhabitants in Flanders, including 3,151,466
males. 3,938,104 inhabitants were aged between 18 and 64 years. In 2013, 51% of the Flemish
people indicated the experience of psychological problems, the most common are sleep prob-
lems, anxiety problems, burnout and mood problems [31]. The Flemish suicide rates were 1.5
times higher than the European mean suicide rate in 2013. In Flanders, in the year 2013, the
total suicide rate per 100,000 inhabitants was 16.3 (in comparison, rates were 6.3 and 32.6 in
Italy and in Lithuania, respectively) [32]. Compared to self-harm rates found in other monitor-
ing studies such as Ireland (199/100,000) [33] and Oxford (293/100,000) [34], Flanders had
lower self-harm rate in 2013 (156/100,000) [35].
Ethics statement
The ethical committee of the University hospital in Ghent approved the study (titled: De epide-
miologie van suïcidepogingen in Vlaanderen: 2008/675) according to the principals expressed
in the Declaration of Helsinki. Data were analyzed anonymously.
Prescriptions
The IMA (agency of the Belgian health insurance; Intermutualistisch Agentschap) supplied the
data on the prescriptions of drugs in Flanders belonging to five ATC (Anatomical Therapeutic
Chemical Classification) codes including (1) N02B analgesics and antipyretics (including para-
cetamol and acetylsalicylic acid) (2) N03A anti-epileptics (including phenytoin, carbamaze-
pine, valproate and pregabalin); (3) N05A antipsychotics (which included haloperidol and
pimozide (4) N06A antidepressants (which included SSRI antidepressants such as citalopram,
sertraline, escitalopram and tricyclic antidepressants such as clomipramine, imipramine, doxe-
pin) and (5) N06B psychostimulants, including agents used for ADHD and nootropics (which
include atomoxetine and methylphenidate). The IMA provided information about the number
of people who received a prescription of the specified medications. Rates of prescribing were
calculated per 1,000 population using annual population estimates from 2008–2013. For exam-
ple, in 2013, 620,337 persons of the 6,365,598 Flemish inhabitants (97.45 persons per 1,000
inhabitants) received a prescription for an antidepressant.
Self-harm
We used data from the monitoring study of self-harm in Flanders on individuals who pre-
sented with self-harm to the emergency departments of 31 General Hospitals and two
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University Hospitals between 1St January 2008 and 31st December 2013. Data collection began
in 2008 in 5 hospitals. The number of participating hospitals gradually increased over the
years, and in 2013 there were 33 participating hospitals. In 2013, there was a 47.7% coverage of
the hospitals in the five counties of Flanders including two University Hospitals and 31 Gen-
eral Hospitals. The University Hospitals have more than 80,000 hospital admissions per year.
The number of hospital admissions in the General Hospitals varies between 10,000 and 35,000
per year. All participating hospitals have an emergency department and 23 hospitals have a
psychiatric department. A semi-structured interview is used by clinicians and nurses as part of
a psychosocial assessment. In this study we used data collected by means of this interview. The
dataset includes information on demographics (age, gender), characteristics of the self-harm
act (including which drug(s) were ingested in overdose), and history of self-harm. Patients
who overdosed on medication from the described ATC groups at any time during the study
period, either alone or in combination with other substances, or in combination with self-
injury, were selected from this population. Event-based data rather than person-based data
were used in the analyses, as the study focused on the ingestion of specific drugs rather than
on personal or clinical characteristics.
Statistical analyses
Prescription rates (numbers of prescriptions per 1,000 population) were calculated for each
year (2008–2013) for the five drug groups using prescription and population data for Flanders.
Frequencies were calculated to describe the sample. All statistical analyses were performed in
R version 3.4.1. Using Generalized Estimating Equations (GEE), the correlation in response
was accounted for by modelling the covariance pattern. By specifying an exchangeable covari-
ance pattern, we assumed that all correlations are the same. Robust standard errors for the esti-
mates were used to compute the 95% confidence intervals. For the GEE analysis the subjects
are nested within years and provinces, the variables history of self-harm, alcohol use (both cate-
gorical variables) and prescription rates (continue variable) were used as covariates and gender
as between subjects factor. The 95% confidence intervals (CI) of the Odds Ratio (OR) are
described. Data analysis was carried out relating to all self-harm acts in which intentional drug
overdose was involved with medication with the following ATC codes N02B (analgesics and
antipyretics), N03A (anti-epileptics), N05A (antipsychotics), N06A (antidepressants) and
N06B (psychostimulants).
Results
During the study period, the monitoring system reported 9,487 episodes of self-harm in the
participating hospitals in Flanders between 2008 and 2013 (Table 1). The majority of self-harm
patients were female (61%). The mean age for both genders was 39 years. Among the 9,487
self-harm acts, 7,388 (78%) involved self-poisoning only (overdose medication and/or self-poi-
soning with pesticides or gases and unspecified chemicals and noxious substances), while
1,622 involved self-injury only and 471 involved both self-poisoning and self-injury. For 6 epi-
sodes, the used method was unknown. The ingestion of an overdose of medication accounted
for 81% of the self-harm episodes. Females reported significant more intentional drug over-
dose during the self-harm act than males (86% vs 72%; χ2 = 320.42, p< .01). In 6.2% of the
self-harm episodes, multiple medications with different ATC codes were used, significantly
more common among females than males (6.9% vs 5.2%; χ2 = 11.52, p< .01). Antidepressants
in combination with antipsychotics were used in 2.7% (n = 259) of the self-harm acts. The sec-
ond most used combination were analgesics and antipyretics and antidepressants (1.7%;
n = 40). In 0.5% (n = 21) of the self-harm episodes three types of medication were used during
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the act for example anti-epileptics in combination with antipsychotics and antidepressants or
analgesics and antipyretics in combination with antidepressants and psychostimulants. In 29%
of the self-harm episodes alcohol was involved during the self-harm act, significantly more
common among males than among females (34% vs 26%; χ2 = 68.75, p< .01). Significantly
more females than males had a history of self-harm episodes (56% vs 47% χ2 = 53.83, p< .01).
Fig 1 shows the trends in prescription rates (e.g. the number of people who received a pre-
scription of the specified medication) for the five ATC groups. The prescription data for Flan-
ders showed a significant increase in prescription rates of analgesics and antipyretics (χ2 =
30.82, p< .001) from 2008 to 2009 from 4.75 (95% CI 2–11.3) to 43.06 (95% CI 32.1–57.5) per
1,000 inhabitants. The prescription rate for analgesics and antipyretics decreased (not signifi-
cantly) with 21% from 43.06 (95% CI 32.1–57.5) in 2009 to 33.88 (95% CI 24.3–47) in 2013.
The prescription rates per 1,000 inhabitants of antidepressants are the highest between 2008
and 2013 compare to the other drug groups and increased (not significantly) with 5% from
92.17 (95% CI 75.8–111.7) in 2008 to 97.45 (95% CI 80.6–117.4) in 2013. Psychostimulants
have been prescribed the least often compared to analgesics and antipyretics, anti-epileptics,
antipsychotics and antidepressants. The prescription rate for psychostimulants and antipsy-
chotics remain stable between 2008 and 2013.
The prescription rates for analgesics and antipyretics, anti-epileptics, antipsychotics, antide-
pressants and psychostimulants in the general population and the percentage of self-harm acts
where intentional drug overdose was used as method (e.g. 81% of the self-harm acts) are
shown in Table 2. The median of prescription rates was higher among females than among
males for four out of five ATC medication groups. The median for medication with code
N06A (antidepressants) was almost two times higher among females (124.9/1,000) than
among males (63.9/1,000). Antidepressants were the most commonly prescribed medication
among both females and males. The median for medication with ATC code N06B (psychosti-
mulants) was more than 3 times higher among males (5.7/1,000) than among females (1.5/
Table 1. Descriptive results of self-harm acts in Flanders from 2008 to 2013 by gender.
Male Female All
Gender (a) 39% (3,672/9,478) 61% (5,806/9,478) 100% (9,478/
9,478)
Mean Age (Sd) 38.6 (14.9) 39.2 (15.8) 39 (15.5)
% [95% CI] (n/
3,699)
% [95% CI] (n/
5,803)
% [95% CI] (n/
9,481)
Self-poisoning (b) 69% [67.4, 70.4]
(2,527)
84% [82.4, 84.6]
(4,854)
78% [77.1, 78.8]
(7,388)
Self-injury (b) 25% [23.9, 26.7]
(927)
12% [11.1, 12.8]
(693)
17% [16.4, 17.9]
(1,622)
Both (b) 6% [5.2, 6.7] (215) 4% [3.9, 5] (256) 5% [4.6, 5.4] (471)
Overdose medication (b) 72% [70.1, 73]
(2,626)
86% [85.6, 87.3]
(5,018)
81% [79.8, 81.4]
(7,644)
Use of alcohol 34% [32.8, 35.9]
(1,259)
26% [25.2, 27,4]
(1,524)
29% [28.5, 30,3]
(2,783)
Previous self-harm episode(s) (c) 47% [45.4, 49]
(1,410)
56% [54.3, 57.2]
(2,647)
52% [51.3, 53.6]
(4,057)
% patients on multiple medications with different
ATC codes (b)
5.2% [4.5, 5.9]
(190)
6.9% [6.2, 7.5]
(401)
6.2% [5.7, 6.7]
(591)
(a) For 9 episodes gender was not known, thus total number of episodes 9,487
(b) Method unknown for 3 males and 3 females
(c) Previous self-harm episodes unknown for 682 males and 1,056 females
https://doi.org/10.1371/journal.pone.0216317.t001
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1,000). From 2008 to 2013, the largest proportion of intentional drug overdoses could be
attributed to medication with ATC code N06A (antidepressants) and N02B (other analgesics
and antipyretics) during self-harm acts with intentional drug overdose in both males (20% and
16%, respectively) and females (25% and 17%, respectively). During the study period, females
(25%) significantly ingested antidepressants more commonly (N06A) during a self-harm act
involving intentional drug overdose than males (20%; χ2 (1) = 12.68, p< .001). The median of
prescription rates for anti-epileptics (N03A) was higher among females (18.9) than among
males (15.9), yet males ingested this medication marginally significantly more commonly dur-
ing a self-harm act with intentional drug overdose than females (3% vs 2%; χ2(1) = 3.63 p =
.057). Overall, the anti-epileptics (N03A) were less commonly ingested in overdose than their
use in the community would predict, in both males (3%) and females (2%).
Fig 1. Trends in prescription rates for the five ATC groups.
https://doi.org/10.1371/journal.pone.0216317.g001
Table 2. Rate of prescriptions, percentage of self-harm episodes with intentional drug overdose as method in
Flanders from 2008 to 2013.
ATC Rate/1,000
median (25th perc– 75th
perc)
% self-harm episodes with intentional drug overdose as
method [95% CI] (n/N)
MALE
Analgesics and
antipyretics
24.5 (25.9–28.8) 16% [14–17] (413/2626)
Anti-epileptics 15.9 (17.6–18.9) 3% [2–4] (75/2626)
Antipsychotics 26.5 (26.9–31.2) 13% [12–15] (349/2626)
Antidepressants 63.9 (65.7–72.3) 20% [19–22] (526/2626)
Psychostimulants 5.7 (6–7.2) 1% [1–2] (28/2626)
FEMALE
Analgesics and
antipyretics
39.3 (41.8–44.3) 17% [16–18] (845/5018)
Anti-epileptics 18.9 (20.3–22.3) 2% [2–3] (107/5018)
Antipsychotics 35.5 (36.4–42.1) 12% [11–13] (616/5018)
Antidepressants 124.9 (127.8–136.2) 25% [23–26] (1230/5018)
Psychostimulants 1.5 (1.6–1.9) 1% [1–1] (36/5018)
https://doi.org/10.1371/journal.pone.0216317.t002
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Table 3 shows the odds ratios of using particular medication in self-harm episodes among
males and females. A particularly relevant finding is that among females who self-harm, the
odds of using antidepressants during the self-harm act were expected to increase with 0.8%
when the rate of prescription increases by 1 prescription/1,000 inhabitants (95%CI 1–1.015).
Among males who self-harm, the odds of using antipsychotic medication during the self-harm
act was expected to increase with 5% when the rate of prescription increases by 1 prescription
/1,000 inhabitants (95% CI 1.017–1.088). Among females who self-harm, the odds of using
antipsychotic medication during the self-harm act was expected to increase with 2% when the
rate of prescription increases by 1 prescription/ 1,000 inhabitants (95% CI 1.006–1.034).
Table 3 also shows the results of the Generalized Estimating Equation for the five medica-
tion groups, per gender, with alcohol use during the self-harm act, and with a history of self-
harm. When males used alcohol during the self-harm act, the odds of using analgesics and
antipyretics during the self-harm act increased significantly by 36% (OR = 1.363, p< .01).
Among females there was no such significant effect (OR = 0.803, >.05). The odds of using
analgesics and antipyretics during a self-harm act increased significantly when there was no
history of self-harm episodes, 28% in males (OR = 0.719, p< .01) and 26% in females
(OR = 0.737, p< .01).
The odds of using anti-epileptics during a self-harm act increased significantly when
females used no alcohol during the self-harm act (OR = 0.54, p< .05) and when there was a
history of self-harm episodes (OR = 1.99, p< .01). Among males there was no such significant
effect.
The odds of using antipsychotic during a self-harm act increased significantly when males
used no alcohol during the self-harm act (OR = 0.739, p< .05) and when there was a history of
self-harm episodes (OR = 2, p< .001). The odds of using antipsychotic during a self-harm act
increased marginally significant when females used no alcohol during the self-harm act
(OR = 0.823, p = .059) and when there was a history of self-harm episodes (OR = 2.409, p<
.001).
The odds of using antidepressants during a self-harm act increased significantly when
males used alcohol during the self-harm act (OR = 1.31, p< .01) and when there was a history
Table 3. Odds ratio due to specific drug categories, prescription rates, alcohol use and history of self-harm per gender.
Male Female
OR (LCL-UCL) p OR (LCL-UCL) p
analgesics and antipyretics Rate 0.988 (0.971–1.004) 0.146 0.996 (0.991–1) 0.073
Alcohol use 1.363 (1.104–1.683) 0.004 0.803 (0.625–1.032) 0.087
History of self-harm 0.719 (0.569–0.922) 0.009 0.737 (0.612–0.887) 0.001
anti-epileptics Rate 1.019 (0.966–1.076) 0.485 1.112 (0.99–1.248) 0.073
Alcohol use 0.712 (0.361–1.406) 0.328 0.54 (0.32–0.91) 0.021
History of self-harm 0.922 (0.494–1.719) 0.798 1.99 (1.284–3.084) 0.002
antipsychotic Rate 1.052 (1.017–1.088) 0.003 1.02 (1.006–1.034) 0.006
Alcohol use 0.739 (0.55–0.933) 0.045 0.823 (0.673–1.007) 0.059
History of self-harm 2 (1.511–2.646) 0 2.409 (1.976–2.937) 0
antidepressants Rate 1.005 (0.991–1.02) 0.498 1.008 (1–1.015) 0.047
Alcohol use 1.31 (1.119–1.533) 0.001 1.093 (0.901–1.327) 0.365
History of self-harm 1.581 (1.244–2.008) 0 1.476 (1.315–1.657) 0
Psychostimulants Rate 0.708 (0.46–1.091) 0.118 0.32 (0.098–1.045) 0.059
Alcohol use 1.616 (0.734–3.513) 0.226 0.741 (0.338–1.623) 0.454
History of self-harm 1.103 (0.528–2.305) 0.794 1.253 (0.645–2.435) 0.505
https://doi.org/10.1371/journal.pone.0216317.t003
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of self-harm episodes (OR = 1.581, p< .001). The odds of using antidepressants during a self-
harm act increased significantly when females had a history of self-harm episodes (OR = 1.476,
p< .001).
There were no significant results with regard to the odds for using psychostimulants, nei-
ther in males nor in females.
Discussion
As far as known to the authors this is the first study of the association between rates of pre-
scription of particular drugs and those of their use as a method of self-harm during an inten-
tional drug overdose at a population level. The results can be summarized as follows. Between
2008 and 2013, antidepressants and analgesics and antipyretics are the most commonly pre-
scribed drugs in females, while antidepressants and antipsychotics were the most prescribed
drugs in males. Antidepressants and analgesics and antipyretics are the most commonly
ingested drugs during a self-harm episode using intentional drug overdose. Analgesics and
antipyretics are more commonly used in first self-harm episodes, while overdoses of antide-
pressants are more commonly involved in repeaters. Antidepressants are significantly more
commonly used in intentional drug overdose among females than among males. These results
are very similar to those of the study of Townsend et al [36] and Tournier et al [21]. Non-fatal
suicidal behaviour may be facilitated by the used medications through means other than the
prescribed medications, a study has shown that a large proportion of those who had used vio-
lent methods had combined suicide method with poisoning. For example, more than half of
those who had completed suicide by drowning had also taken other substances such as alcohol
and opioids [37].
Preceding a discussion of these findings in terms of their relevance for the prevention of
suicidal behaviour a few methodological issues need to be addressed. The study was carried
out in subjects admitted to general hospitals, therefore the self-harm study group included no
subjects with self-harm who were treated in other facilities or medically unidentified. We also
have no information about patients who needed an intensive or surgical procedure following
their severe self-harm act, as they were not seen by a psychologist/psychiatrist directly after
admission. This indicates a possible under reporting of the real number of people who self-
harm in Flanders. Since the number of self-harm acts involved is large, the findings are likely
to be representative. This limitation may have a bias on the types of medication that was used
during the self-harm act. The patients who were not admitted at the emergency department
after their self-harm episode may have taken a different kind of medication compared to the
patients who were admitted. The over-the-counter availability of analgesics and antipyretics
was not taken into account in this study. The presence of analgesics and antipyretics is proba-
bly underestimated given that these drugs are widely available without prescriptions. The types
of medication ingested during the self-harm act were identified during the psychosocial assess-
ment with the patient and not using objective measurements, such as a blood test. The accu-
racy of the results thus depends on the patient statements. As a final limitation of this study,
we can state that the semi-structured interview that was used during the psychosocial assess-
ment is not a standardized and validated instrument.
Implications for suicide prevention
Numerous factors contribute to the occurrence of suicide which is never the consequence of
one single cause of stressor. The Integrated Motivational- Volitional (IMV) model of suicidal
behaviour is a tri-partite model that describes the biopsychosocial context in which suicidal
ideation and behaviour may emerge, the factors that lead to the emergence of suicidal ideation
Medication used in intentional drug overdose
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and the factors that govern the transition from suicidal ideation to suicide attempts/ death by
suicide [38]. The final phase of the IMV model outlines the factors (volitional moderators;
VMs) that govern the transition from suicidal ideation to enaction. VMs can be environmental
and having access to means of suicide is an important risk factor for suicide [38, 39]. Access to
means for self-harm or suicide is an important component of suicide prevention, and a limita-
tion in such access has been clearly shown to reduce rates of suicidal behaviour [40]. Since this
study shows an increase in annual rates of prescription of antidepressants and in their inges-
tion during self-harm episodes, particularly among repeaters, the availability of medication
indeed appears to be an important given for the prevention of self-harm. Physicians have to
take in consideration that prescribing medication contributes to this availability. Depression is
a key risk factor for repetition of self-harm [41] and it is therefore likely that repeaters have
been prescribed antidepressants more commonly than first-ever self-harmers. The latter may
have thus less access to prescribed medication and therefore more commonly use analgesics
and antipyretics, which are easily available without prescription. The association between anti-
depressant prescriptions and their use in self-harm does not implicate that taking such medi-
cation lead to an increase in self-harming behaviour. Given the link between self-harm and
psychiatric disorders, and depression in particular, the availability of antidepressants will be
greater in individuals who self-harm than in the general population (probably in a similar way
as patients who die from a heart attack more commonly will have taken cardiology
medication).
Antipsychotic drugs are the third most commonly used medication during an episode of
intentional drug overdose, and an increase in their use was paralleled by an increase in the
number of prescriptions of antipsychotic medication in Flanders. Such a positive correlation is
not found for analgesics and antipyretics, which are the second most commonly used drugs
for self-harm. This is probably due to the fact that these drugs are widely available without the
need for a prescription.
The current results underline the importance of the availability of medication for the preven-
tion of suicidal behaviour. The beneficial effects of limiting the availability of medication on the
occurrence of suicidal behaviour have already been shown elsewhere, including restrictions in
the number of prescriptions and prescribed tablets and complete withdrawal as a prevention
strategy in Ireland, the UK and Denmark [42–46]. It should be noted that these examples
involve analgesics medications that are toxic in overdose, and the examples thus do not general-
ize to psychotropic medications. In effect, it would be potentially dangerous to recommend
reducing or withholding such psychotropic medications on the basis of a plan to reduce suicide
rates as this could well lead to an increase in suicide rates [47–49]. In addition, more recently
developed psychotropics such as SSRIs are relatively safe when taken in overdose without alco-
hol or other medication [50]. Nevertheless, the current findings suggest an important role for
physicians and pharmacies in this context. Prescribing small amounts of medication and close
monitoring of their intake are crucial. Returning unused medication to the pharmacy is advis-
able [21]. Physicians should be aware of other medications their patients have access to [51].
Prescription Drug Monitoring Programs (PDMP) as developed in the US provide a good exam-
ple of a database which contains information about the dose, supply and prescriber of scheduled
drugs the patient has filled and which is accessible to prescribing physicians and to pharmacies
[52, 53]. Training, particularly of physicians who deal with patients at high risk of suicide, can
also be an effective method to influence prescribing behaviour and to highlight the importance
of collaboration between colleagues and health services [54, 55]. Moreover, consideration
should be given to psychotherapy, such as cognitive therapy, problem-solving therapy or inter-
personal psychotherapy (whether or not in combination with antidepressants), its efficacy in
preventing repetition of self-harm has been clearly demonstrated [40].
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Conclusion
This study shows an increase in the odds of using antidepressants and antipsychotics in epi-
sodes of self-harm when the rate of their prescription increases. While analgesics and antipy-
retics and antidepressants are the most commonly prescribed drugs among females and
antidepressants and antipsychotics are the most prescribed medication among males, antide-
pressants and analgesics and antipyretics are the most frequently used drugs in episodes of
self-harm. While analgesics and antipyretics are most commonly ingested during first episodes
of self-harm, antipsychotics and antidepressants are more commonly used by repeaters. These
findings suggest that the availability of medication ingested during the act of self-harm. Conse-
quently, there are a number of implications for the prevention of suicidal behaviour: the num-
ber of prescriptions and tablets should be limited and the return of unused medication to
pharmacies is advisable. These issues should be addressed in the education and training of
physicians and pharmacies.
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